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Summary. Recent studies on the intraperitoneal adminis- 
tration of radiolabeled monoclonal antibodies indicate that 
the diaphragm and, in particular, the lymphatics associated 
with the diaphragm are more involved in the transport of 
such high-molecular-mass moieties than was earlier sus- 
pected. The current study examines the role of the dia- 
phragm in the i.p. transport of an IgG2a murine mono- 
clonal antibody, 5G6.4, by observing the effect on the 
absorption of the antibody produced when the diaphragm 
has been scarred. Normal, sham-operated, and dia- 
phragmatically scarred (abrasions made with 600-grade 
sandpaper) female Sprague Dawley rats (150-250 g) were 
administered intraperitoneal injections of 1251abeled 5G6.4 
in a volume of 2.0 cm3. Approximately 5 gg antibody pro- 
tein was administered in the individual 19-gCi injections 
per rat. Scarring was effective in partially blocking the 
amount of labeled antibody that crossed the diaphragm. 
Mean diaphragm levels (% injected dose/g) of 125I-labeled 
5G6.4 from the scarred group were 16.8% lower than 
values from the sham-operated rats and 37.2% lower than 
those from the control rats. The blockade was effective in 
slowing the appearance of the labeled antibody in the sys- 
temic circulation. The half-time to absorption was signifi- 
cantly prolonged in the scarred group; mean tl/2 absorption 
values of 2.5 h for the control group, 5.3 h for the sham- 
operated group, and 9.6 h for the diaphragmatically 
blocked group were recorded. Scarring the diaptu'agm re- 
duced the mean maximum blood concentration by 27.6% 
over the control group and 23.9% over the sham-operated 
group. The mean time to maximum blood concentration 
was lengthened by 93.0% over the control group and 
35.3% over the sham-operated group due as a result of 
scarification. Presumably this impedence to absorption 
would increase the time that the radiolabeled antibody 
bathed the peritoneal space. The scarred group also had the 
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largest "system mean residence time" (162.5 h) compared 
to the sham-operated (147.9 h) and control (118.7 h) 
groups. These values further verify the effect of surgery on 
the kinetics of the i.p. administered radiolabeled mono- 
clonals. This work demonstrates that scarifying the dia- 
phragm does alter the kinetics of the i.p. administered 
monoclonal antibodies and supports the concept that trans- 
diaphragmatic lymphatic absorption is an important route 
of antibody clearance from the peritoneal cavity. 
Introduction 
It is known that the intraperitoneal monoclonal antibody 
delivery is a pharmacokinetically rational approach to the 
delivery of radioantibody to malignäncies localized to the 
peritoneal cavity [20]. While rational, the mechanism of 
antibody absorption from this cavity has not been exten- 
sively studied. Absorption of fluid from the peritoneal 
cavity is carried out, at least in part, by the terminal lym- 
phatics, called lacunae, located in the diaphragm [14]. 
Lacunae communicate with the peritoneal cavity via sto- 
matal openings between mesothelial cells that lead into 
channels formed by the combined processes of the me- 
sothelial and lacunar endothelial cells [14, 15]. Dedrick et 
al. [3], in justifying a pharmacokinetic rationale for perito- 
neal drug administration in the treatment of ovarian cancer, 
reported that most drugs absorbed from the peritoneum 
enter the portal system with the transdiaphragmatic lym- 
phatics contributing only modestly to absorption. In sup- 
port of this statement the authors cite data from Popovich 
et al. [12] showing that the peritoneal permeability is 
roughly inversely proportional to the square root of molec- 
ular mass. The published fange of those experiments, how- 
ever, is <10 kDa, far less than the 150 kDa of an intact IgG. 
Wahl et al. [20] have shown that the rates of uptake of 
several i. p. administered IgG's, IgM' s, and their fragments 
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Fig. 1. Histogram from Wahl et al. [20] showing the equivalence of the 
absorption rate constants (mean _+ SD) of several i.p. administered 
radiolabeled monoclonal antibodies 
molecular masses from 50 kDa (Fab 225.28S) to 900 kDa 
(IgM BA-1 and IgM FT166). Figure 1 is a histogram from 
those data showing the equivalence of the absorption rate 
constants of the antibodies studied [20]. Multiple compari- 
son tests (Scheffe F-test and Dunnet t-test) found no differ- 
ence between any of the groups [20]. Current unpublished 
data indicate further that the diaphragm and indeed the 
lymphatic system associated with this tissue are more in- 
volved in the egress of these antibodies from the peritoneal 
cavity than was earlier thought [1, 5, 8] (and Barrett, Wahl 
and Wagner, unpublished data). Our ongoing studies to 
model the kinetics of intraperitoneal antibody delivery 
have shown that levels of radiolabeled antibody activity 
peak in the diaphragm and its draining lymphatics several 
hours before maximal blood levels are reached (Barrett et 
al. unpublished data). The early high levels in these tissues 
seem to indicate that the i.p. delivered radiolabeled mono- 
clonal crosses the diaphragm to an appreciable level con- 
sistent with the diaphragmatic lymphatics contributing to a 
major extent to the egress of the antibody. 
Tsilibary and Wissig [14] have shown that the patency 















Fig. 2. Histogram from Wahl et al. [20] showing the effect of tumor 
burden on the absorption rate constants (mean _+ SD) of i.p. adminis- 
tered 5G6.4 and UPC-10 (11 with tumor; [] normal) 
conditions in the peritoneal cavity. Contractile components 
of the mesothelial and endothelial cells seem to be respon- 
sible for maintaining the conformation of both stomata and 
underlying channels and presumably also for effecting 
changes in the patency of stomata. They observed numer- 
ous patent stomata when the diaphragm is relaxed and 
when intraabdominal fluid pressure is raised (as with the 
addition of fluid from an i.p. injection) [14]. This appears 
to be an adaptive response to expedite removal of fluid 
from the peritoneal cavity. Also, ascites accompanying 
peritoneal parasitic infection resulted in hypertrophy of 
mesothelial cells and fewer patent stomata even though the 
peritoneal cavity was filled with abundant ascitic fluid and 
intraabdominal pressure had presumably increased [14]. 
This could explain, at least in part, the local effect of an i. p. 
"tumor burden" and why the absorption rate constant from 
the peritoneal cavity of tumor-laden mice was significantly 
(P <0.005) different from that of normal mice (eight times 
smaller) in the findings of Wahl et al. [20]. Figure 2 
(adapted from [20]) shows the effect of tumor burden on 
the absorption of two IgG2 a murine monoclonal antibod- 
ies, the ovarian cancer-"specific" IgG2ak 5G6.4 and the 
myeloma IgG2ak UPC-10, administered i. p. 
The principal aim of this study is to determine whether 
the absorption of an antiovarian IgG2a (5G6.4) antibody is 
altered by scarification of the peritoneal surface of the 
diaphragm. The resulting fibrosis and scarring may induce 
a blockade of diaphragmatic absorption [4]. Therefore, if 
the terminal lymphatics are in fact responsible for a signif- 
icant component of the absorption of antibodies given i. p., 
a significant difference in the absorption of the labeled 
antibody between the experimental and control groups 
should be detected. A third group (sham-operated) was 
added to determine whether there is a significant effect due 
to surgery alone, without diaphragmatic blockade, on any 
measurable effects associated with absorption into the sys- 
temic circulation. The main objectives of this study are to 
measure the extent to which the diaphragm is blocked by 
scarification, to demonstrate an improved i.p. delivery 
advantage in scarred animals over administration in non- 
treated animals, and to evaluate the effect of diaphragmatic 
blockade on tissue distribution. This could have therapeu- 
tic significance in that the regional delivery advantage of 
i.p. administration could potentially be further exploited 
by limiting the egress of antibody from the peritoneal 
cavity. 
Materials  and methods  
Monoclonal antibodies. The mouse IgG2a monoclonal antibody, 5G6.4 
was studie& 5G6.4 is known to react preferentially with ovarian and 
other epithelial cancers [19]. The antibody was purified from ascites 
using staphylococcal protein A chromatography [19]. The molecular 
mass and purity of the purified antibody were verified on 7.5% sodium 
dodecyl sulfate/polyacrylamide gels [7]. 
Radiolabeling. All labelings were conducted using 1251 (New England 
Nuclear, Boston, Mass), by the iodogen method (Pierce Chemical, Rock- 
ford, Ill) [10], 1 mCi being used to label 100 ~g antibody protein. Free 
lodine was removed from the mixture after labeling by anion-exchange 
resin. Iodine incorporation for this procedure is in the 50%- 80% range. 
The specific activity of the administered injection mixture was approxi- 
mately 4 ~tCi/gg. Freedom from iodine contamination was demonstrated 
by silica gel thin-layer chromatography with 50% ethyl acetate and 50% 
ethanol [ 18]. 
Administration. Two weeks prior to injection, 35 adult female Sprague- 
Dawley rats (150-200 g) were separated into three groups (15 experi- 
mental, 10 sham-operated, and 10 control rats). The 15 experimental and 
the 10 sham-operated rats had a small midline incision cut into the 
abdomen. The peritoneal surface of the diaphragm of the experimental 
group rats was gently rubbed with a moistened piece of 600-grade sand- 
paper [4]. Talc (U.S.P. 8476, Mallinckrodt Inc., St. Louis, MO) was then 
dusted onto the abraded surface as a further irritant to induce fibrosis. 
The sham-operated group was merely probed under the diaphragm with 
the forefinger. The peritoneal cavity of the treated animals was closed 
with 4-0 chromic suture. Closure of the outer wound was completed by 
stapling with automatic wound clips. Injection mixtures were prepared 
using a Capintec radioisotope calibrator (CRC-4R). Rats were given 
single 19-gCi injections of 125I-labeled 5G6.4. The individual doses were 
administered in a 2.0-cm 3 volume of saline at 37 ° C. Rats were anesthe- 
tized with ether, weighed, and numbered prior to injection. The i.p. 
injections were administered with a 27-gauge needle attached to a 3-tal 
syringe. Rats that died during the study or in which the attempted i.p. 
injection was not successful were subsequently dropped from the study. 
Blood samples (= 13 over time) were drawn from the tail vein through 
pasteur pipettes and weighed on glassine paper using a Mettter balance. 
Samples were then placed in 12 x75-mm test-tubes and capped. Rats 
were returned to the group cage overnight. At the end of the 7-day 
experiment, blood samples and the excised thyroid, anterior mediastinal 
lymph nodes, kidneys, and diaphragms were weighed and counted in a 
Packard 5780 gamma counter with the appropriate corrections for count 
decay. Several diaphragms from each group were removed for examina- 
tion at the conclusion of the study. Perpendicular histological sections to 
the ventral plane of the diaphragm approximately 5 gm thick were cut, 
stained with H & E and photographed. Examination of the radiolabeled 
components in the blood serum and i.p. fluid was carried out on three rats 
at 45 min, 2 h, and 4 h. Following centrifugation, sizing analysis of the 
superuatant was carried out on a Pharmacia FPLC system with a Super- 
ose 6 gel filtration column. Fractions were collected and counted on a 
Packard 5780 gamma counter. 
Pharmacokinetics. Blood samples were collected over a 7-day period. 
The data were corrected for decay and plotted as time/activity curves for 
whole blood. Pharmacokinetic analysis was completed using RSTRIP 
[11]. The program employs a nonlinear least-squares subroutine in its 
fitting module. A weighting factor of 1/y was used for each fit. For each 
time course exhaustive curve strippings up to four exponentials were 
generated. Those which gave physiologically impossible parameters (in- 
correct sign in front of coefficient or exponent) were subsequently 
dropped from the model comparison. The remainder were used as initial 
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Fig. 3. Mean blood levels (mean _+ SEM) from i.p. administered 125I-la- 
beled 5G6.4 in three treatment groups of female Sprague Dawley rats 
(150-250 g) 
estimates for fitting using nonlinear least-squares and the associated 
F-tests (MSC, model selection criteria in RSTRIP), r 2, and parameter 
standard errors were evaluated for the best fits. Individual rat blood level 
curves were fitted and modeled from the % kg dose/g units (Units of 
concentration based on the % of the original injected counts available in 
the blood at time t, normalized to the weight of the animal). The parame- 
terized values were then converted into standard pharmacokinetic units. 
Mean data were used to generate the histograms in Results. 
Statistical analysis. SYSTAT [ 13] was used to complete the individual 
analyses of variance and tests for homogeneity of variance. Linear con- 
trasts from the original one-way analyses of variance were made for 
partial comparisons across pairs of treatment groups. Box and whisker 
plots were made for the volume of distribution, blood clearance, and 
absorption phase half-life. 
Results 
Experimental 
Mean blood level curves of 125I-labeled 5G6.4 for the three 
treatment groups are shown in Fig. 3. The integrity of the 
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Fig. 4. Activity profiles of the/aSI-labeled 5G6.4 species 
at 45 min, 2 h, and 4 h after i. p. injection observed in the 
serum and intraperitoneal fluid by FPLC radiochromatog- 
raphy 
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Fig. 5 A, B. Perpendicular histological 
slices of rat diaphragm (10 x ) excised 
at sacrifice (7 days) after i. p. administra- 
tion of 125I-labeled 5G6.4. A Normal rat 
diaphragm. B Diaphragm (top) frorn 
scarified rat showing granulation layer 
formed due to scarring (middle) and at- 
tached normal liver (bottom) 
Fig. 4. Early serum samples examined by FPLC radiochro- 
matography show no indication of any secondary 125I-la- 
beled metabolic products. This verifies the work of Him- 
melsbach et al. [6] with 125I-labeled 5G6.4. Later assays in 
the serum, kidneys, and liver also show no evidence of 
formation of species of either higher or lower molecular 
mass after i.p. administration of 125I-labeled 5G6.4 though 
the urine contains free iodine [6]. The blood levels (see 
Fig. 3) indicate that there is a delayed appearance of the 
labeled antibody in the scarified group. Moreover, on the 
basis of the mean blood levels, the maximum concentra- 
tions of the diaphragmatically blocked and the sham- 
operated group were lower than those of the control group. 
Finally, the ascent of the absorption phase is rauch steeper 
in the control and sham groups than in the diaphragmati- 
cally blocked group. The pharmacokinetics section, which 
follows, gives a more detailed analysis of the parameter- 
ized blood levels. 
Figure 5 shows a photomicrograph of a histological 
section (10 × magnification) of a diaphragm from one of 
the control group rats (A) and a scarified diaphragm (B), 
showing the granulation layer formed from the fibrosis due 
to scarring and the adhesion of this layer to the liver. The 
tissue was cut perpendicular to the ventral plane. The ad- 
hesion appears to be caused by the thick granulation tis- 
sue containing particles of talc and sand that were used 
for scarification. Notice that the diaphragm itself appears 
normal. 
Figure 6 shows a histogram of mean 125I-labeled 5G6.4 
levels in the kidney, anterior mediastinal lymph nodes, and 
diaphragm with their respective standard error bars. The 
scarified group had significantly lower levels in the kidney 
(P = 0.027) and diaphragm (P = 0.048) than the other two 
groups (control and sham). While the measured levels in 
the lymph nodes were lower in the scarified and sham- 
operated groups, they were statistically equivalent to those 
of the control group. Mean radioantibody levels in the 
thyroid are shown in Fig. 7. These levels represent mostly 
free iodine. There exists a statistically significant differ- 
ence (P <0.001) between the diaphragmatically-blocked 
and the other two groups. This may be due to slower 
antibody egress from the peritoneal cavity. Longer expo- 
sure of the labeled compound may increase the total 
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Fig. 6. Mein1 tissue levels (mean _+ SEM) from i. p. administered I25I-la- 
beled 5G6.4 in three treatment groups of female Sprague Dawley rats 













Fig. 7. Mean thyroid levels (mean + SEM) from i.p. administered 125 I- 
labeled 5G6.4 in three treatment groups of female Sprague Dawley rats 
(150-250 g) 7 days post injection 
P harmacokinetic modeling 
Individual subject (rats) sets of concentration (kg % dose 
injected/g)/time data were fitted for each antibody in every 
rat to a bi-exponential curve using the method of least- 
squares in the program RSTRIP [11]. Initial estimates were 
obtained by the curve-stripping routine of the same pro- 
gram. Below is the schematic diagram of the standard 
one-compartment open model used to fit each blood/time 
curve. The equations are straightforward as follows. 
C = (e -Kt- e -kar) (1) 
where FD/V is analogous to Co (blood concentration at 
time = 0) after intravenous administration. K is the overall 
elimination rate constant for the labeled antibody or the 
fractional rate of labeled antibody elimination. 
Rate of elimination CL 
K = [Ab] Va (2) 
The rate of elimination can be written as follows: 
d [Abl 
- CLC (3) 
dt 
where [Ab] is the amount in the body, Va is the volume of 
distribution in the plasma compartment, CL is the blood 
clearance (volume/time), and C is the blood concentration. 
Integrating from 0 to infinity yields. 
- f d [Ab] = CL f Cdt 
o o 
(4) 
From here an expression for blood clearance can be 
derived. 
CL = i .p.  dose 
- -  ( 5 )  
F (AUC)0~oo 
where F is the bioavailability or the fraction of the dose that 
is actually absorbed, and AUC is the area under the curve. 
Hence, the blood concentration of these two antibodies can 
be explained by the classical one-compartment open model 
with first-order input (see Scheme): 
i kA K 
Mean residence time (MRT) parameters are often used 
to measure the variation in steady-state blood concentra- 
tions [16] and to approximate the amount of systemic ex- 
posure of the ding and/or antibody in question [1, 16]. It is 
the latter that we are concerned with here. The system 
MRT is the mean residence time during which the com- 
pound remains in the entire model - the body. 
AUMC0~oo 
System MRT - (6) 
AUC0~oo 
AUMc is the area under the first-moment curve. The 
plasma MRT is the mean residence time in which the 
compound remains in the central or plasma compartment. 
AUC0~~ 1 
Plasma MRT - - (7) 
CO kel 
where kel is the elimination rate constant from the plasma 
compartment. For the one-compartment model, ke~ equals 
the overall first-order elimination rate constant, K, since 
elimination is assumed to be from the plasma compartment 
only. 
Table 1 contains the mean pharmacokinetic parameters 
derived from the blood levels of rats of each group. The 
sample size of each group is included with the results of a 
one-way analysis of variance for two levels of confidence 
(90% and 95%). In addition, partial comparison tests (lin- 
ear contrasts made on the C-matrix from the original anal- 
yses of variance) are included for each parameter. The 
symbols = and ~ under the partial comparison heading 
refer to statistical equivalence and significant difference 
respectively. The P-values associated with these linear 
contrasts refer to the probability of the null hypothesis - 
the probability that the two groups in the contrast are 
equivalent. 
It is evident, as Table 1 indicates, that indeed there is an 
effect of surgery with respect to the kinetics of 125I-labeled 
5G6.4 administered intraperitoneally. Both the dia- 
phragmatically blocked and sham-operated groups clear 
the blood more slowly (0.123 ml/h and 0.138-0.185 ml/h) 
and values are distributed to a lesser extent (Vä = 14.8 ml 
and 14.74-20.71 ml) than those of the non-operated con- 
trol group. However, the plasma MRT values of all three 
groups are statistically equivalent. This seems to indicate 
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Table 1. Pharmacokinetic parameter summary and statistical inference across treatment groups 
Mean parameter a Treatment group 
Control Diaphragmatic Sham 
block 
(n= 8) (n= 11) (n=7) 
Analysis of variance significance results 
= 0.05 c~ = 0.1 Partial comparison tests 
tl/2 absorption (h) 2.49 9.59 5.34 Yes Yes 
(0.27) (1.83) (0.88) (P = 0.005) 
Time at Cmax (h) 12.72 24.55 18.15 No Yes 
(0.97) (4.36) (4.37) (P = 0.070) 
Crnax (% kg dose inj/g) 0.670 0.485 0.637 Yes Yes 
(0.058) (0.030) (0.075) (P = 0.029) 
Vd/F (ml) 20.71 14.85 14.74 No Yes 
(2.53) (1.45) (3.02) (P = 0.125) 
CL/F (ml/h) 0.185 0.123 0.138 Yes Yes 
(0.025) (0.007) (0.012) (P = 0.022) 
System MRT (h) 118.72 162.51 147.88 No No 
(8.90) (16.00) (13.63) 
Plasma MRT (h) 115.15 122.13 100.33 No No 
(8.86) (11.37) (16.67) 
Control = sham; (P = 0.203 
Control ~e d.block; c~ = 0.05; p = 0.001 
Sham ~ d.block; c~ = 0.05; P = 0.047 
Control = sham; P = 0.546 
Control ~ d.block; c~ = 0.05; P = 0.028 
Sham = d.block; P = 0.125 
Control = sham; P = 0.669 
Contml ~ d.block; c~ = 0.05; P = 0.014 
Sham ~ d.block; c~ = 0.05; P = 0.048 
Control ~ sham; c~ = 0.1; P = 0.089 
Control ~ d.block; c~ = 0.1; P = 0.065 
Sham = d.block; P = 0.971 
Control ~: sham; ~z = 0.1; P = 0.057 
Control ~ d.block; c~ = 0.05; P = 0.007 
Sham = d.block; P = 0.496 
Control = sham; P = 0.192 
Control ~ d.block; c~ = 0.05; P = 0.034 
Sham = d.block; P = 0.478 
Control = sham; P = 0.438 
Control = D.block; P = 0.683 
Sham = d.block; P = 0.227 
a Vd, volume of distribufion in plasma compartment; Cmax, maximum blood concentration; CL, blood clearance; F, bioavailability (fraction of dose 
absorbed); MRT, mean residence time 
that there exists a difference in tissue and/or plasma protein 
b inding  between the operated and non-operated groups. 
The system MRT in the scarified group is greater than in 
the other two groups, yet not  significantly different from 
that of the sham-operated group. It may be that adhesions 
due to surgery are an added site of b inding  or at least of 
transient retardation of entry to the systemic circulation of 
the labeled m A b  and therefore the operated groups ex- 







Control Sham D. B[ock 
Fig. 8. Mean absorption rate constants (mean + SEM) across treatment 
groups from i.p. administered ~25I-labeled 5G6.4 female Sprague Daw- 
ley rats 
mean blood levels (see Fig. 3) indicate, the t ime to maxi- 
m u m  blood concentrat ion is longer and the max imum 
blood concentrat ion is smaller in the diaphragmatically- 
blocked group than in the other two groups. The actual 
values can be found in Table 1. Yet, for both parameters, 
the sham-operated group appears to be between the control 
and scarified groups. Statistically, the sham-operated 
group is equivalent  to the control group with respect to 
time at Cmax and equivalent  to the scarified group with 
respect to Cmax. The most  dramatic result of this procedure 
lies in the tl/2 absorption values (see Fig. 8). The sham- 
operated and control groups are statistically equivalent  
(mean values of 2.49 h and 5.38 h), but  the group with the 
diaphragmatic block (9.59 h) is significantly different from 
both these groups. 
With respect to the analysis of these data, the mean 
values, although the standard errors are included, are not 
always informative enough to explain the results from an 
analysis of variance. Figure 9 a, b, c shows box and whisker 
plots for blood clearance, tl/2 absorption, and volume of 
distribution. The plots illustrate the effect of the spread of 
the data on the conclusions from the analysis of variance 
and subsequent  pairwise comparisons.  Figure 9 b  shows 
the spread of the tl/2 absorption values for each group 
relative to their means.  Even with the larger variation in the 
scarified group, it was found to be significantly different 
from both of the other groups at a 95% confidence level. 
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Fig. 9 a - c .  Box and whisker plot of (A) blood clearance values, (B) tl~2 
absorption values, and (C) volume distribution values across treatment 
groups 
371 
mechanism of antibody uptake from the peritoneal cavity. 
Additional studies with more tissues at earlier time points 
and with other antibodies may increase our understanding. 
These experimental observations indicate that the 
transdiaphragmatic absorption of antibodies is making ä 
substantial contribution to the total radioantibody absorp- 
tion from the peritoneal cavity. This is in contrast to prior 
studies suggesting that transperitoneal membrane absorp- 
tion is the major route of antibody egress. The absorption 
rate constants we observe are significantly higher than 
those predicted by permeability area product/molecular 
mass functionalities [3, 9]. While the design of our experi- 
ment does not specificälly address the relative contribution 
to absorption from each route, it is also possible that this is 
not a constant ratio. Specifically, variations in i.p. fluid 
volume and pressure may result in varying stomatal open- 
ing, which may alter the proportion of antibody leaving 
through the diaphragmatic lymphatics. More studies are 
necessary and are in progress. 
It is possible that the delayed i.p. fluid absorption 
caused by diaphragmatic blockade may offer a significant 
improvement in the regional delivery advantage of i.p. 
administration to intraperitoneal tumors by increasing the 
time these tumors are bathed with the radioantibody [20]. 
Further, if combined with peritoneal lavage for therapeutic 
use, ädditional improvements in the regional delivery 
advantage might be made [17]. Certainly, our invasive 
procedure is not an option for human therapy, though i.p. 
carcinomätosis by itself may block the lymphatics and the 
flow of fluid from the peritoneal cavity [2, 8, 17]. Possibly, 
an alternative method of blocking the diaphrägm will in- 
crease the time that the labeled compound is exposed to the 
peritoneal cavity and thus increase the regional delivery 
advantage offered by i.p. administration. Even if not im- 
mediately applicable clinically, this study strongly sup- 
ports our hypotheses regarding the importance of the dia- 
phragmatic lymphatics in the physiology of peritoneal 
transport of high-molecular-mass protein species. 
Acknowledgements: The technical assistance of Andrew Kucharski, Tore 
Gutowski, Chris Henry, and Gayle Jackson is rauch appreciated. Sup- 
ported by CA 41 531 and CA 33 802 awarded by the P. H. S. 
Discussion 
The present study indicates that the kinetics of distribution 
of i.p. delivered radiolabeled murine IgG2a monoclonal 
antibody 5G6.4 can be altered by scarification of the dia- 
phragm. This approach significantly slows the rate of ab- 
sorption of the labeled antibody, delays the time to its peak 
blood level, and reduces the magnitude of these peak 
levels. These effects are almost certainly due to a high level 
of obstruction of the entrance to the transdiaphragmatic 
lymphatics by scarring, as can be seen by light microscopy. 
While it is known that swelling of the mesothelial cells of 
the diaphragm due to infection can result in the closure of 
stomatal openings, infections in the operated groups were 
not observed. The less marked effects in the sham-operated 
group and the control group add further support to the 
concept that the diaphragm has a significant role in the 
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